

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
119P/PCT2/USAPPLICATION NO.
10/554,240INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
DONG, Zheng XinFILING DATE
Oct. 21, 2005GROUP/EXAMINER
Unknown/Unknown

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A	5,482,698	Jan. 9, 1996	Griffiths			
	B	5,525,338	Jun. 11, 199	Goldenberg			
	C	5,795,909	Aug. 18, 1998	Shashoua et al.			
	D	5,843,903	Dec. 1, 1998	Schally et al.			
	E	5,948,750	Sep. 7, 1999	Garsky et al.			
	F	6,077,499	Jun. 20, 2000	Griffiths et al.			
	G	6,191,290	Feb. 20, 2001	Safavy			
	H	6,207,660	Mar. 27, 2001	Sessler et al.			
	I	2002 0094964	Jul. 18, 2002	Chen et al.			
	J	2002 0115596	Aug. 22, 2002	Garsky et al.			
	K	2003 0064053	Apr. 3, 2003	Liu et al.			
	L	2003 0064984	Apr. 3, 2003	Ng et al.			
	M	2005 0070470	Mar. 31, 2005	Coy et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	N	96/40210	Dec. 19, 1996	WIPO PCT			
	O	97/19954	Jun. 5, 1997	WIPO PCT			
	P	02/34237	May 2, 2002	WIPO PCT			
	Q	02/87497	Nov. 7, 2002	WIPO PCT			
	R	0 450 461 (A2, A3, B1)	Oct. 9, 1991	EP			
	S	0 450 480 (A2, A3, B1)	Oct. 9, 1991	EP			
	T	1 118 336	Jul. 25, 2001	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	U	FUSELIER, et al., "An adjustable release rate linking strategy for cytotoxin-peptide conjugates," Bioor. Med. Chem. Lett., 2003, 10:799-803.
	V	HUANG, et al., "Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis," Chem. Biol., 2000, 7:453-461.
	W	KOVACS, et al., "Recovery of pituitary function after treatment with a targeted cytotoxic analog of lutenizing hormone-releasing hormone," PNAS, 1997, 94:1420-1425.
	X	NAGY, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," PNAS, 95:1794-1799.
	Y	SAFVY, et al., "Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery," Bioconjug. Chem., 2003, 14:302-310

EXAMINER /Andrew D. Kosar/

DATE CONSIDERED 08/30/2009